















https://A systematic review and meta-analysis of remote
ischemic preconditioning for vascular surgeryPhilip W. Stather, MBChB, FRCS(vascular), MD,a Julie Wych, PhD,b and Jonathan R. Boyle, FRCS, MD,a
Cambridge, United KingdomABSTRACT
Background: Remote ischemic preconditioning (RIPC) is a method of preparing the body for a later prolonged ischemic
episode to protect against subsequent detrimental effects. This study aimed to identify the effects of RIPC in vascular
surgery.
Methods: A standard Preferred Reporting Items for Systematic Reviews and Meta-Analyses search was conducted of
randomized controlled trials of RIPC in patients undergoing open or endovascular aneurysm repair, carotid endarter-
ectomy, or lower limb bypass reporting on mortality and renal or cardiac outcomes. Random-effects meta-analysis was
performed using Review Manager 5.3 (The Nordic Cochrane Center, Copenhagen, Denmark).
Results: A total of 13 randomized controlled trials in the meta-analysis included 548 patients in the RIPC cohort and 549
controls. There was no significant difference in mortality, renal dysfunction, myocardial infarction, myocardial injury, or
length of stay between the groups, with subgroup and sensitivity analysis showing no significant difference.
Conclusions: Current evidence demonstrates no benefit of RIPC in vascular surgery. Further large multicenter trials of
RIPC in major vascular surgery should be considered. (J Vasc Surg 2019;70:1353-63.)
Keywords: Remote ischemic preconditioning; Renal failure; VascularRemote ischemic preconditioning (RIPC) is a method
of exposing the body to a stimulus in a controlled
manner to initiate a cascade of effects to protect against
the detrimental effects of a subsequent, perhaps more
prolonged ischemic episode. This protection results
from the RIPC generation of free radicals leading to the
release of adenosine, bradykinin, and opioid receptor
agonists, which leads to activation of matric metallopro-
teinases inducing the release of growth factors that are
thought to be cytoprotective.1 RIPC aims to induce the
initial ischemia-reperfusion injury in a controlled manner,
thus beginning activation of the cytoprotective effects
that will then already be activated before a larger
ischemia-reperfusion insult.
Previous studies and meta-analyses have investigated
theeffects ofRIPC inboth cardiac andnoncardiac surgery,
but the evidence remains inconclusive. Overall, there is no
difference in all-causemortality2 and no difference in car-
diac clinical outcomes2,3 but significant reduction inhe Department of Vascular Surgery, Addenbrookes Hospitala; and the
cal Research Council Biostatistics Unit, University of Cambridge, School
nical Medicine.b
conflict of interest: none.
nal material for this article may be found online at www.jvascsurg.org.
ondence: Philip W. Stather, MBChB, FRCS(vascular), MD, Department of
lar Surgery, Addenbrookes Hospital, Hills Rd, Cambridge CB2 0QQ, UK
il: philstather@doctors.org.uk).
tors and reviewers of this article have no relevant financial relationships to
se per the JVS policy that requires reviewers to decline review of any
script for which they may have a conflict of interest.
14
ht  2019 The Authors. Published by Elsevier Inc. on behalf of the
ty for Vascular Surgery. This is an open access article under the CC
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
doi.org/10.1016/j.jvs.2019.03.025cardiac troponin T3 and inconclusive evidence regarding
renal outcomes2,4 and stroke rates.2,3 Vascular surgery in-
volves clamping of themain arterial supply to a particular
territory; therefore, the ischemic insult is potentially signif-
icant in this cohort of patients, and hence the role of RIPC
has the potential to be more pronounced. This study
aimed to identify the effects of RIPC in vascular surgery.METHODS
The systematic review followed quality reporting
guidelines set by the Preferred Reporting Items for
SystematicReviewsandMeta-Analyses.5MEDLINE,Embase,
and Health and Psychosocial Instruments databases were
searched using Ovid Online (version OvidSP_UI03.04.02.112;
Ovid Technologies, Inc, Norwood, Mass) and PubMed in
July 2018. There were no language restrictions or filters
used to restrict study designs. In addition, reference lists
were searched for further studies to be included.
Eligibility criteria and study selection. Potential studies
were screened by two of the authors (P.S. and J.B.). For in-
clusion within the systematic review, the study had to be
a randomized controlled trial, had to include RIPC, and
had to have included participants undergoing surgery
to the abdominal aorta, carotid artery, arteriovenous fis-
tula, or arterial bypass. Each study must have reported
data on mortality, renal dysfunction, myocardial infarc-
tion, or myocardial injury.
Data collection. Data were extracted independently by
P.S. and J.B., with any discrepancies discussed. The
following outcomes were recorded: mortality, renal
impairment, myocardial infarction, myocardial injury,
length of stay, and length of stay on the intensive care unit.1353
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ReviewManager 5.3 (TheNordic Cochrane Center, Copen-
hagen, Denmark),6 Stata version 15.1 (StataCorp LLC, Col-
lege Station, Tex), and PASS version 14.0.8 (NCSS, LLC,
Kaysville, Utah).
Separate analyses were performed for each individual
outcome, with all possible papers included where they
had published results on the outcome under analysis.
Meta-analysis was performed using the Mantel-Haenszel
method, with a standard continuity correction of 0.5. A
random-effectsmodel was used because of the variability
of methods of RIPC between studies and the variability in
types of procedures performed both between the studies
and within individual studies. An a level of #.05 was used
to determine statistical significance.
Sensitivity analyses. Separate analyses were performed
for participants undergoing each individual vascular pro-
cedure where possible. In addition, sequential removal of
each individual study from each analysis was performed,
and subgroup analysis for those undergoing similar
methods of RIPC was performed where possible.
Assessment of study quality. The quality of non-
randomized studies was assessed using the Grading of
Recommendations Assessment, Development, and Eval-
uation (GRADE) scale.7 The study quality was assessed by
examining patient randomization, blinding, and data
completeness.
Assessment of heterogeneity. For each of the four out-
comes, we assessed the homogeneity of the treatment
effect across studies using Cochran Q. This test has low
power when the number of studies included in the
meta-analysis is low8; therefore, a higher statistical sig-
nificance of P < .1 was assumed. In addition to test for
heterogeneity, Higgins I2 (95% uncertainty interval) was
calculated.9 I2 provides a measure of the degree of
inconsistency across the different study resultsdthe
percentage of total variation across studies that can be
attributed to heterogeneity rather than to chance.8
Values lie between 0% and 100%, 0% indicating no
heterogeneity, 25% low heterogeneity, 50% moderate
heterogeneity, and 75% high heterogeneity.8,9
Publication bias. Funnel plots with pseudo-95% con-
fidence intervals were produced for all outcomes.
Asymmetry in funnel plots was assessed to check for
publication bias and to test for small-study effects. Small-
study effects were tested using the model proposed by
Harbord et al,10-12 which tests the null hypothesis of no
small-study effectswhere statistical significance of P< .05
is assumed.
Assessment of sample size and power calculation.
Sample size and power calculations were based on the
odds ratios (ORs) for each of the four outcomesd
mortality, renal dysfunction, myocardial infarction, andmyocardial injury. The proportion of events in the control
group was calculated as the total number of events in
the control group across all studies/total controls across
all studies, assuming the same observation time across
all studies. We test the null hypothesis (H0) that the
OR ¼ 1 comparing RPIC with controls against the alterna-
tive hypothesis (H1) that the OR s 1. Power and sample
size curves for ORs <1 were plotted to show the power
for exposure to RIPC being associated with a lower
odds of mortality, renal failure, myocardial infarction,
and myocardial injury.RESULTS
Identification of relevant studies. Search terms
“vascular OR aneurysm OR carotid OR bypass OR fistula”
AND “preconditioning OR pre-conditioning” and “ran-
domized controlled trial OR RCT” were combined, result-
ing in 310 titles after removal of duplicates. All abstracts
were reviewed, revealing 22 articles that were potentially
relevant. A single article was identified through review of
references. Of the 23 articles, 4 were removed because of
being reviews,1,4,13,14 2 used anesthetic agents only,15,16 2
were protocols,17,18 and 2 were not relevant,19,20 leaving 13
articles for inclusion21-33 (Fig 1).
Study characteristics. The publication dates of the
eligible studies ranged from 2007 to 2018. All studies
were prospective randomized controlled trials. The study
size ranged from 40 to 201 participants, with a total of
582 patients in the RIPC cohort and 585 patients in the
control cohort. Study characteristics are outlined in
Table I, with a variety of methods of RIPC used and a
range of vascular procedures. Study baseline character-
istics are summarized in Table II and baseline medica-
tions in Table III. There was a standard representation of
cardiovascular risk factors reported for a vascular cohort
of patients, with significant differences within the studies
as expected by the small sample sizes, and a large vari-
ation in uptake of standard cardiovascular medications.
Study quality was assessed using GRADE score
(Supplementary Tables I and II, online only).
Combined outcomes. All extracted data are outlined
in Table IV. Pooled analysis from all papers revealed
no significant difference in mortality (5.3% RIPC vs 6.0%
control; OR, 1.05 [0.48-2.29]; P ¼ .25), renal impairment
(17.4% RIPC vs 19.1% control; OR, 0.89 [0.56-1.39];
P ¼ .60), myocardial infarction (10.5% RIPC vs 12.9%
control; OR, 0.78 [0.50-1.20]; P ¼ .25), or myocardial
injury (22.4% RIPC vs 25.5% control; OR, 0.81 [0.44-1.51];
P ¼ .51; Figs 2-5).
Length of stay on the intensive care unit was reported in
three studies, showing no conclusive difference in me-
dian length of stay across the studies.21,24,28 There was
also no significant difference in overall length of stay in
any study.21,22,24,28,30,32,33
Fig 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses diagram.
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shows heterogeneity statistics for the four outcomes
considered. The test for heterogeneity at the 10% level is
not significant for any of the four outcomes after vascular
procedure in comparing RIPC with controls. Considering
the values of I2, all outcomes have low levels of incon-
sistency across studiesdmortality (I2 ¼ 22%), renal
impairment (I2 ¼ 30%), myocardial infarction (I2 ¼ 2%),
and myocardial injury (I2 ¼ 41%)dand therefore
variability across studies in each outcome cannot be
attributed to heterogeneity.
Sensitivity analyses. Sensitivity analysis was possible for
patients undergoing abdominal aortic aneurysm (AAA)
repair only, showing no significant difference in any out-
comes (Supplementary Table IV, online only). Further
sensitivity analysis was performed by exclusion of indi-
vidual studies and analyzing those studies using forearm
ischemia only, both of which did not significantly alter
results.
Publication bias. Testing for funnel plot asymmetry and
small-study effects ideally should include at least 10
studies in a meta-analysis10,12; here, only renal impair-
ment and myocardial infarction outcomes have 10
studies. The funnel plots in all four outcomes
(Supplementary Fig 1, online only) suggest weak
evidence of asymmetry; it is difficult to draw firm
conclusions about funnel plot asymmetry because of thesmall number of studies in each of the four outcomes
investigated. Supplementary Table V (online only) shows
test results for small-study bias effects for each outcome.
Only for the mortality outcome is there evidence of
small-study effects (P ¼ .037); however, this test has low
power because of the small number of studies included
in the meta-analysis.
Supplementary Fig 2 (online only) shows power curves
for the four outcomes considered. Assuming a signifi-
cance level of .05 in all cases, taking mortality as an
outcome, group sample sizes of 550 in both the control
and RIPC groups achieves 13.3% power to detect an OR
of 0.8. For renal impairment as an outcome, group sam-
ple sizes of 525 in both the control and RIPC groups
achieves 27.8% power to detect an OR of 0.8. Myocardial
infarction with group sample sizes of 525 in both the
control and RIPC groups achieves 21.4% power to detect
an OR of 0.8; myocardial injury with group sample sizes
of 300 in both the control and RIPC groups achieves
21.4% power to detect an OR of 0.8.
DISCUSSION
The study identified no significant difference in mortal-
ity, renal dysfunction, myocardial infarction, myocardial
injury, or length of stay in patients undergoing RIPC for
vascular surgery.
An early systematic review of RIPC in vascular surgery13
was unable to identify any advantage of RIPC, and
Table I. Background of all studies comparing remote ischemic preconditioning (RIPC) and controls in vascular surgery
Year Country Center Funding Blinding No. of RIPC patients No. of controls
Ali 2007 United Kingdom Single Public Double 41 41
Fudickar 2014 Germany Single Unclear Single 20 20
Garcia 2016 United States Single Public Single 100 101
Healy 2015 Ireland Multi Nil Nil 99 99
Li 2013 China Single Unclear Double 31 31
Menting 2015 The Netherlands Multi Nil Single 38 38
Mouton 2015 United Kingdom Single Public Double 34 35
Murphy 2014 Ireland Single Unclear Double 31 31
Pedersen 2018 Denmark Single Public Nil 72 70
Thomas 2016 New Zealand Single Nil Single 42 43
Walsh 2009 United Kingdom Single Public Unclear 18 22
Walsh 2010 United Kingdom Single Public Unclear 22 18
Walsh 2010 United Kingdom Single Public Single 34 36
AAA, Abdominal aortic aneurysm; CIN, contrast-induced nephropathy; EVAR, endovascular aneurysm repair; IR, ischemia-reperfusion.
aCIN risk is defined as an estimated glomerular filtration rate <45 mL/min/1.73 m2 or <60 mL/min/1.73 m2 with diabetes or two additional risk factors,
such as peripheral vascular disease, heart failure, age >75 years, anemia, dehydration, diuretics, and nonsteroidal anti-inflammatory drugs.




disease Hypertension Diabetes Current smoker
RIPC Control RIPC Control RIPC Control RIPC Control RIPC Control
Ali 74 75 24 27 51 63 5 5 27 32
Fudickar 68 68 45 30 30 25 45 50
Garcia 69 69 45 42 16 11 37 31
Healy 69 69 18 13
Li 62 67 77 58 45 29 23 19
Menting 71 73 78 67 22 28
Moulton 72 72 38 26 77 71
Murphy 75 69 13 16 64 52 23 16
Pedersen 72 73 28 21 56 67 7 11 54 43
Thomas 74 75 29 25 10 19 21 14
Walsh 74 76 28 18 44 55 17 9 6 4
Walsh 75 72 5 17 54 88 5 0 36 17
Walsh 70 68 35 31 68 58 12 31 21 22
Percentages in each cohort are reported.
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take a meta-analysis. A previous meta-analysis of 37
studies across all types of surgery4 had identified a
potential benefit for RIPC in renal protection; however,
this was only in user-defined acute kidney injury and
did not stand up to renal guidelines. A recent meta-
analysis of patents undergoing percutaneous coronaryintervention34 revealed a significant reduction in myocar-
dial infarction and acute kidney injury; however, these
results are not reproduced in patients undergoing coro-
nary artery bypass grafting.3
This study has several limitations. The majority of the
studies included were small and of moderate quality,
with a possibility of publication bias seen within the
Table I. Continued.
Surgery Method Cycles of ischemia-reperfusion Phase of RIPC
Open elective AAA Direct clamp 2  5/5 minutes First
Lower limb bypass Sevoflurane anesthesia
and direct clamp
2 sevoflurane, 1 clamp, 6/6 minutes First
Open AAA, EVAR, carotid,
lower limb bypass
Forearm ischemia 3  5/5 minutes Second
Open AAA, EVAR, carotid,
lower limb bypass
Forearm ischemia 4  5/5 minutes First
Open AAA Forearm ischemia 3  5/5 minutes First
IR procedure þ CIN riska Forearm ischemia 4  5/5 minutes First
Open AAA, EVAR Forearm ischemia 3  5/5 minutes First
Open AAA Forearm ischemia 3  5/5 minutes First
Open ruptured AAA Forearm ischemia 4  5/5 minutes First
Open AAA, EVAR, lower
limb bypass
Forearm ischemia 3  5/5 minutes 24 hours preoperatively,
3  5/5 minutes immediately preoperatively
First and second
EVAR Lower limb ischemia
thigh tourniquet
2  10/10 minutes, one limb, then the other First
Open AAA Direct clamp 2  10/10 minutes, one limb, then the other First
Carotid Lower limb ischemia
thigh tourniquet




infarction Cardiac failure Renal impairment Stroke
RIPC Control RIPC Control RIPC Control RIPC Control RIPC Control
39 46 20 32 5 2 5 2 20 5
70 60 45 30 20 5
78 72 24 23 7 6 3 2 17 21
16 19 8 7 23 16
16 26
36 44 19 22 17 19
15 3 18 20
61 55 22 13 19 7
21 19 11 13
33 40 13 10
33 18
18 22
9 3 27 25
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variability within the studies included in terms of types
of procedure investigated; not all studies reported on
every outcome, which could potentially be construed
as reporting bias, and one study used second-phase
RIPC.23 The timing from RIPC to surgery was not consis-
tent, ranging from daily RIPC episodes to anesthesiainduction to intraoperative, which could affect the
degree of RIPC protection at the time of cross-clamping.
Three studies23,24,30 reported on vascular procedures
combined; therefore, the decision was made to include
all studies into vascular surgery as a whole, with separate
subgroup analyses where possible. However, comparing
the validity of RIPC outcomes in such a heterogeneous
Table III. Baseline medications of all studies comparing remote ischemic preconditioning (RIPC) and controls in vascular
surgery
Beta blocker Calcium channel blocker
RIPC Control RIPC Control
Ali 39 41 24 24
Fudickar 65 65 40 25
Garcia 71 61 19 21
Healy 36 39 18 27
Li 52 61 42 23
Menting 67 64 33 22
Moulton 35 31
Murphy 32 36 41 16
Pedersen





Percentages taking each medication are reported.
Table IV. All outcomes comparing remote ischemic preconditioning (RIPC) vs controls in vascular surgery
Author
ITU stay, days, median (IQR)
Length of stay, days,
median (IQR) Myocardial injury, No. (%)
RIPC Control P value RIPC Control P value RIPC Control P value
Ali 1 (1) 3 (3) .03 9 (6) 11 (7) .23 5 (12) 16 (39) .01
Fudickar 5 (3-9) 5 (3-16) NS 1 1 NS
Garcia 22 (22) 25 (24.7) .74




Murphy 6 (4-7) 4 (3-7) .07 15 (12-20) 14 (11-18) .67 16 (51.6) 9 (29.0) .11
Pedersen
Thomas 5 (3-8) 6 (3-8) .82 18 (42.9) 21 (48.8) .58
Walsh 5 (4-8) 4 (3-7) .51 1 (5.6) 2 (9.1) .73
Walsh 11 (9-14) 10 (7-17) .79
Walsh 1 (2.9) 1 (2.8) .97
IQR, Interquartile range; ITU, intensive therapy unit; NS, not significant.
aRenal failure.
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be taken into account in interpreting the data. The sys-
temic impact of open AAA repair is inherently much
greater than that of endovascular aneurysm repair
(EVAR) or even carotid endarterectomy, and including
all of these procedures in a single analysis could mask
an underlying significant finding in an individual proced-
ure. In addition, one study included ruptured AAA, which
has a much larger physiologic burden than elective
repair. To minimize this effect, this study undertook asubgroup analysis of AAA repair (both open and EVAR)
in addition as a sensitivity analysis; however, there were
insufficient data to reproduce this for lower limb bypass,
carotid endarterectomy, and EVAR or open AAA repair
individually.
Although inconclusive, these data suggest that for pro-
cedures with a short ischemia time, such as carotid end-
arterectomy and EVAR, RIPC is unlikely to be of any
significant physiologic benefit. The data regarding
open AAA repair are less conclusive as the study by
Table III. Continued.
ACE inhibitor Antiplatelet Statin
RIPC Control RIPC Control RIPC Control
32 37 37 9 39 39
45 70 80 70 40 50
44 49 87 89 77 73
26 31 83 85 84 84
29 19 35 52
25 36 39 56
59 49 77 71
54 60 80 80
40 33 40 40
60 60 16 12 79 77
44 45 67 46 72 23
32 55 45 44 41 61
91 89 91 86
Table IV. Continued.
Myocardial infarction, No. (%) Renal impairment, No. (%)
In-hospital or 6-week
mortality, No. (%) Composite
RIPC Control P value RIPC Control P value RIPC Control P value RIPC Control P value
2 (5) 11 (27) <.01 3 (7) 12 (30) .009 2 (5) 3 (7) .77
0 (0) 0 (0) NS
4 (4) 5 (5) .74 1 (1) 3 (3) .15 0 (0) 0 (0) NS
8 (8) 13 (13) .36 22 (22) 29 (29) .33 3 (3) 2 (2) 1 14 (14) 19 (19) .45
2 (6.4) 1 (3.2) .50 0a (0) 0a (0) NS 0 (0) 0 (0) NS
2 (5.6) 2 (5.6) 1 2 (5.6) 0 .49
5 (14.7) 2 (5.7) 16 (47.1) 12 (34.3) 0 (0) 3 (8.6)
4 (12.9) 2 (6.5) .67 17 (54.8) 11 (35.5) .20 3 (9.7) 1 (3.2) .61
26 (36.1) 30 (42.9) .502 14a (19.4) 17a (24.3) .31 14 (19.4) 24 (34.3) .04
2 (4.8) 2 (4.7) .44 2 (4.8) 3 (7.0) 1 (2.4) 0 (0)
1 (5.6) 1 (4.5) .99 4 (22.2) 2 (9.1) .29 1 (5.6) 0 (0) .45 3 (16.7) 4 (18.2) .99
1 (4.5 1 (5.5) .99 11 (50.0) 10 (55.6) .73 3 (13.5) 0 (0) .16 14 (63.6) 7 (38.9) .12
0 (0) 0 (0)
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Volume 70, Number 4Pedersen et al29 did highlight a reduced mortality in
those with a ruptured AAA undergoing RIPC, and the
study by Ali et al17 identified a shorter intensive care
unit stay, less myocardial injury and infarction, and lower
renal impairment; however, the studies by Li et al,26
Murphy et al,28 and Walsh et al32 showed no differences
in these outcomes for elective open AAA repair. Last,
each of the outcome measures remains underpowered
to show a significant difference between RIPC and con-
trols; therefore, an appropriately powered, multicentertrial of RIPC in those undergoing open AAA repair should
be considered to truly evaluate the role of RIPC in this
cohort specifically.CONCLUSIONS
In this meta-analysis and systematic review of 13 studies
in vascular surgery, RIPC did not significantly affect mor-
tality, renal dysfunction, myocardial infarction, myocar-
dial injury, or length of stay.
Fig 2. Meta-analysis of studies reporting mortality after vascular procedure, comparing remote ischemic pre-
conditioning (RIPC) with controls. CI, Confidence interval; OR, odds ratio.
Fig 3. Meta-analysis of studies reporting renal impairment after vascular procedure, comparing remote ischemic
preconditioning (RIPC) with controls. CI, Confidence interval; OR, odds ratio.
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Fig 4. Meta-analysis of studies reporting myocardial infarction after vascular procedure, comparing remote
ischemic preconditioning (RIPC) with controls. CI, Confidence interval; OR, odds ratio.
Fig 5. Meta-analysis of studies reporting myocardial injury after vascular procedure, comparing remote ischemic
preconditioning (RIPC) with controls. CI, Confidence interval; OR, odds ratio.
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Supplementary Table II (online only). Grading of Recommendations Assessment, Development, and Evaluation (GRADE)













1097 (12) Serious Not serious Not serious Very serious Not serious 29/548 33/549 1.05 (0.48-2.29)
Renal impairment
1057 (11) Serious Not serious Not serious Serious Serious 92/528 101/529 0.89 (0.56-1.39)
Myocardial infarction
1051 (11) Serious Not serious Not serious Very serious Serious 55/524 68/527 0.78 (0.50-1.20)
Myocardial injury
580 (7) Serious Not serious Serious Very serious Serious 64/286 75/294 0.81 (0.44-1.51)
OR, Odds ratio.
Supplementary Table III (online only). Heterogeneity statistics from the meta-analysis of the four outcome measures of
mortality, renal impairment, myocardial infarction, and myocardial injury after vascular procedure, comparing remote
ischemic preconditioning (RIPC) with controls
Outcome No. of studies
Heterogeneity test
I2, % (95% uncertainty level)Q df P value
Mortality 9 10.19 8 .25 22 (0-63)
Renal impairment 10 12.94 9 .17 30 (0-67)
Myocardial infarction 10 9.18 9 .42 2 (0-63)
Myocardial injury 7 10.19 6 .12 41 (0-75)
df, Degrees of freedom; I2, Higgins I2 statistic; Q, Cochran Q statistic.
Supplementary Table I (online only). Grading of Recommendations Assessment, Development, and Evaluation (GRADE)







and personnel (performance bias) Completeness of data
Ali þ þ þ þ
Fudickar þ þ e e
Garcia þ e þ e
Healy þ þ e þ
Li þ þ þ þ
Menting ? ? þ þ
Moulton þ þ þ þ
Murphy þ þ þ þ
Pedersen þ e e þ
Thomas þ þ e ?
Walsh þ e ? þ
Walsh þ e ? þ
Walsh þ e e þ
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Supplementary Table IV (online only). Sensitivity analysis comparing all studies reporting on open or endovascular
abdominal aortic aneurysm (AAA) repair
Outcome No. of studies RIPC Control OR P value
Mortality 7 23/249 31/248 0.69 (0.38-1.23) .20
Renal dysfunction 7 65/249 64/248 0.99 (0.65-1.51) .95
Myocardial infarction 7 41/249 48/248 0.79 (0.48-1.28) .34
Myocardial injury 3 22/90 27/94 0.77 (0.39-1.49) .43
OR, Odds ratio; RIPC, remote ischemic preconditioning.
Supplementary Table V (online only). Results using
Harbord modified test for small-study effects11,12 from the
meta-analysis of the four outcome measures of mortality,
renal impairment, myocardial infarction, and myocardial
injury after vascular procedure, comparing remote
ischemic preconditioning (RIPC) with controls
Outcome No. of studies Bias SE P value
Mortality 9 1.74 0.68 .037
Renal impairment 10 0.17 1.14 .884
Myocardial infarction 10 0.87 0.75 .282
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Supplementary Fig 1 (online only). Funnel plots with pseudo-95% confidence intervals for all studies reporting
mortality, renal impairment, myocardial infarction, and myocardial injury comparing remote ischemic pre-
conditioning (RIPC) and controls. OR, Odds ratio; SE, standard error.
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Supplementary Fig 2 (online only). Power and sample size curves for studies reporting mortality, renal impair-
ment, myocardial infarction, and myocardial injury comparing remote ischemic preconditioning (RIPC) and
controls. OR, Odds ratio.
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